Companies · Biotechnology

Asana Medical, Inc.

MIAMI LAKES · Biotechnology

Diligence memoA one-page analyst read on Asana Medical, Inc. — recommendation, valuation, rhythm, risks.
$2.9M
Total raised · real
2
Rounds
7.3×
Latest step-up
Top 68%
Sector rank · raised
Seed
Latest stage · inferred · Thu Jun 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Asana Medical, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.91× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
  • Within the normal band (91% of peer median) for its niche.
Dormant
  • Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Asana Medical, Inc. is one of 4293 Biotechnology companies tracked from MIAMI LAKES. By capital raised it ranks in the long tail (ahead of 33% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
19
Investors (latest)
2013
Year incorporated
2016-06-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2014-09-30 Raised $1.5M (real) Modeled valuation $64M (est)$1.5M$64MSeed2014Pre-Seed · 2014-09-30 Raised $200K (real) Modeled valuation $11M (est)$200K$11MPre-Seed2014Seed · 2016-06-30 Raised $1.5M (real) Modeled valuation $64M (est)$1.5M$64MSeed2016+$200K+$1.5MCumulative $3.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.5M · 2014
Bridge · Seed-stage$200K · 2014smaller follow-on
Seed extension$1.5M · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$64.5M
Base estimate est.
$1.0M
Conservative case
$506.0M
Upside case
$7.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $64.5M · 2014-09-302014Pre-Seed · modeled $11.0M · 2014-09-30Seed · modeled $64.5M · 2016-06-302016
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
10.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$1.7M/yr
Capital velocity
11.8 yr
On record since
2014
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.4× of median
This company$2.9M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.8× of median
This company$1.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.0× above median
This company$64.5M
Sector median$64.2M

Raised more than 33% of sector peers (real $). Modeled value above 50% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #105 of 175.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Mimedx Group, Inc. · Seed Raised $8.2M · modeled $177.6M (est)Kenjockety Biotechnology, LLC · Seed Raised $4.0M · modeled $177.6M (est)Helocyte, Inc. · Seed Raised $4.0M · modeled $177.5M (est)CytoDel, INC. · Seed Raised $4.1M · modeled $173.4M (est)Finch Therapeutics, Inc. · Seed Raised $4.5M · modeled $165.8M (est)Cordex Systems, Inc · Seed Raised $6.4M · modeled $164.2M (est)Viking Therapeutics, Inc. · Seed Raised $3.7M · modeled $162.3M (est)Escalier Biosciences B.V. · Seed Raised $3.5M · modeled $155.4M (est)Corino Therapeutics, Inc. · Seed Raised $3.5M · modeled $154.3M (est)Captozyme Inc. · Seed Raised $3.4M · modeled $151.0M (est)BluDiagnostics, Inc. · Seed Raised $4.5M · modeled $151.0M (est)FORGE Life Science, LLC · Seed Raised $3.6M · modeled $149.5M (est)Asana Medical, Inc. (this company) Raised $2.9M · modeled $64.5M (est)Asana Medical, Inc.
CompanyStageRaised · realValue · estvs peer med.
Mimedx Group, Inc.Seed$8.2M$177.6M2.50×
Kenjockety Biotechnology, LLCSeed$4.0M$177.6M2.50×
Helocyte, Inc.Seed$4.0M$177.5M2.50×
CytoDel, INC.Seed$4.1M$173.4M2.44×
Finch Therapeutics, Inc.Seed$4.5M$165.8M2.33×
Cordex Systems, IncSeed$6.4M$164.2M2.31×
Viking Therapeutics, Inc.Seed$3.7M$162.3M2.28×
Escalier Biosciences B.V.Seed$3.5M$155.4M2.19×
Corino Therapeutics, Inc.Seed$3.5M$154.3M2.17×
Captozyme Inc.Seed$3.4M$151.0M2.12×
BluDiagnostics, Inc.Seed$4.5M$151.0M2.12×
FORGE Life Science, LLCSeed$3.6M$149.5M2.10×
Asana Medical, Inc. this companySeed$2.9M$64.5M0.91×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.5M2014-09-30$7.3M$64.5M90%
Pre-Seed$200K2014-09-30$1.1M$11.0M85%
Seed$1.5M2016-06-30$7.3M$64.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.5M2014-09-30
    • First recorded raise — entered as Seed.
    • 19 investors on this round.
  2. Pre-Seed$200K2014-09-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 7.3× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  3. Seed$1.5M2016-06-30
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 7.3× larger than the prior — scaling up.
    • 19 investors on this round.
Intelligence
2017 ~Q2
Modeled next raise · ~10mo cadence
$4.4M
Modeled next size est.range $2.8M$7.0M
7.3×
Last step-up
$1.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Reginald Hardy1 other2014-09
Richard C. Bulman, Jr.1 other2014-09
Christine Sapan2014-09
Christine S. Sapan2014-09
Gary Ramphal2014-09
Gary S. Ramphal2016-06
Gerard Coombs2014-09
Gerard S. Coombs2014-09
Marc Ramer2014-09
Michael Phalen2014-09
Richard Bulman2014-09
Richard S. Bulman, Jr.2016-06
Registry & provenance

Asana Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1625411
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Rythera Therapeutics Inc.BiotechnologySeed$1.3M$21.8Mnetwork1 shared operator · same sector · same stage
Soricimed Biopharma Inc.BiotechnologySeed$2.9M$68.6Msame sector · same stage
Personalized Stem Cells, Inc.BiotechnologySeed$2.9M$70.4Msame sector · same stage
Antria, Inc.BiotechnologySeed$2.9M$63.9Msame sector · same stage
Florida Biomed, LlcBiotechnologySeed$2.9M$68.8Msame sector · same stage
Animated Dynamics, Inc.BiotechnologySeed$3.0M$56.7Msame sector · same stage
TGS Knee Innovations, IncBiotechnologySeed$2.8M$68.0Msame sector · same stage
Crossfire Medical IncBiotechnologySeed$3.0M$57.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
MDNA Life Sciences, Inc.BiotechnologyPre-Seed$25.9M86%
Atea Pharmaceuticals, Inc.BiotechnologySeries D+$4.4B85%
Carna Inc.BiotechnologySeed$12.4M84%
Anogen Life Sciences, Inc.BiotechnologyPre-Seed$15.8M84%
Mimio Health, IncBiotechnologySeed$24.9M84%
Akonni Biosystems IncBiotechnologySeries A$64.2M84%
AlmataBio, Inc.BiotechnologySeed$14.5M84%
Axenic Health Solutions, Inc.BiotechnologySeed$451K84%
Frequently asked
How much funding has Asana Medical, Inc. raised?
Asana Medical, Inc. has raised approximately $2.9M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Asana Medical, Inc.'s estimated valuation?
Provath's modeled valuation for Asana Medical, Inc. is approximately $64.5M (modeled range $1.0M–$506.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Asana Medical, Inc. at?
Asana Medical, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Thu Jun 30.
What does Asana Medical, Inc. do and where is it based?
Asana Medical, Inc. operates in the Biotechnology sector, based in MIAMI LAKES.
Explore related

See where Asana Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Asana Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.